Evaluation of Protein in the Urine in Patients Receiving Bevacizumab

Veterans Affairs (VA) North Texas Health Care System

Status: Completed

Conditions: Colon Cancer; Rectal Cancer

Study type: Observational

Funder types: Other; Other U.S. Federal agency

Identifiers

NCT00849394

A07-3423

07-097

122007-001 ;

Details and patient eligibility

About

This is a clinical research study to look at the incidence of proteinuria (a condition in which urine contains an abnormal amount of protein) caused by shortened infusions (given into the vein over 10 or 15 minutes) of bevacizumab (a medication prescribed for colon, lung, or breast cancer). There are currently no published studies or clinical data looking at how safe shortened infusions of bevacizumab are in relationship to the side effect of proteinuria. We hypothesis that shortened infusions of bevacizumab will result in an increased risk for proteinuria compared to the standard infusions of this agent.

Enrollment: 106 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients must be 18 years older
• Patients must be receiving his/her first dose of bevacizumab
• Patients must sign an informed consent

Exclusion criteria

• Patients receiving > 10 mg/kg doses of bevacizumab

Trial design

106 participants in 1 patient group

1

Description:

Shortened infusions of bevacizumab